Oneness Biotech and Zhongtian Shanghai announced that their newly developed COVID-19 treatment, SNS812, has successfully achieved key benchmarks in its Phase 2 clinical trials. The nucleic acid drug demonstrated strong safety and significant clinical efficacy against highly immune-evasive COVID-19 variants, including JN.1, KP1-4, and LB.1, which account for 90% of strains in the trial.
Conducted at National Taiwan University Hospital and other top medical institutions, the trial followed rigorous international standards. SNS812, administered through aerosol inhalation, outperformed a placebo in reducing the time to symptom resolution, including common symptoms like fever, sore throat, and shortness of breath. The trial also found the drug reduced the median time for virus positive-to-negative conversion to just 2.9 days in the high-dose group.
As COVID-19 continues to mutate, current vaccines and treatments struggle to keep pace, but SNS812’s broad efficacy across multiple variants positions it as a potential game changer. Oneness Biotech aims to pursue international collaborations and regulatory approvals for emergency use authorization (EUA) and global distribution of SNS812 in major markets. The results offer hope for improved COVID-19 management in the face of persistent viral mutations.
